Related Experiment Video
Updated: Jul 13, 2026

Studying the Activity of Neuropeptides and Other Regulators of the Excretory System in the Adult Mosquito
Published on: August 24, 2021
Maxadilan, a PAC1 receptor agonist from sand flies
Ethan A Lerner1, Aurel O Iuga, Vemuri B Reddy
1Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Charlestown, Massachusetts, United States. ethan.lerner@cbrc2.mgh.harvard.edu
Maxadilan, a peptide from sand fly saliva, potently activates the PAC1 receptor. This discovery offers insights into leishmaniasis and vasodilator peptide research.
Area of Science:
- Biochemistry
- Pharmacology
- Parasitology
Background:
- A potent vasodilator peptide, maxadilan, was identified in 1991 from sand fly salivary glands.
- Maxadilan is a 61 amino acid peptide with significant biological activity.
Purpose of the Study:
- To discuss the activation of mammalian PAC1 receptors by maxadilan.
- To explore the connection between maxadilan and leishmaniasis.
Main Methods:
- Isolation and characterization of maxadilan from sand fly saliva.
- Studies on the interaction of maxadilan with PACAP receptors, specifically PAC1.
Main Results:
- Maxadilan was confirmed as a potent activator of the mammalian PAC1 receptor.
- PAC1 receptor is one of three receptors for pituitary adenylyl cyclase-activating polypeptide (PACAP).
Conclusions:
- Maxadilan's specific and potent activation of PAC1 receptor is a key finding.
- The research provides a basis for understanding maxadilan's role in leishmaniasis transmission and pathogenesis.
More Related Videos
10:46A Calcium Bioluminescence Assay for Functional Analysis of Mosquito (Aedes aegypti) and Tick (Rhipicephalus microplus) G Protein-coupled Receptors
Published on: April 20, 2011
06:45Electrophysiological Recording of The Central Nervous System Activity of Third-Instar Drosophila Melanogaster
Published on: November 21, 2018
Related Concept Videos
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Anthelminthic Agents
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Cholinergic Antagonists: Pharmacokinetics
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...